Silence Therapeutics plc (SLNCF) Return on equity 2022–2025
Silence Therapeutics plc (SLNCF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-142.2%FY2025 · since FY2022: -184.9% → -142.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -142.2% | -108.4 pp |
| FY2024 | -33.8% | +212.8 pp |
| FY2023 | -246.6% | -61.7 pp |
| FY2022 | -184.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SLNCF financial trends
SLNCF RevenueSLNCF Net incomeSLNCF Net marginSLNCF Gross profitSLNCF Gross marginSLNCF Operating incomeSLNCF Operating marginSLNCF Operating cash flowSLNCF Free cash flowSLNCF Capital expendituresSLNCF Stock buybacksSLNCF Dividends paidSLNCF Total assetsSLNCF Total liabilitiesSLNCF Shareholders’ equitySLNCF overview →